Sarepta Therapeutics, Inc. (SRPT) Form 8-K — Jun 4, 2026
Sarepta Therapeutics held its annual meeting of stockholders on June 4, 2026, where shareholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan. The new Equity Incentive Plan supersedes the 2018 plan and makes 6,740,000 shares available for issuance, while the ESPP makes 1,500,000 shares available for employee purchases. Shareholders also elected five Class I directors to the board, including CEO Douglas S. Ingram, and approved the advisory vote on executive compensation for 2025.
Key figures
- Shares Outstanding
- 105571146
- Quorum percentage
- 77.97
- Eip shares available
- 6740000
- Espp shares available
- 1500000
- Shares present at meeting
- 82309288
Price after filing
Close on the filing date to close N calendar days later (from $16.66). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.